-
Mashup Score: 5
PURPOSE Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared with gefitinib as a first-line treatment for locally advanced or metastatic EGFR-mutated non–small-cell lung cancer (NSCLC; ClinicalTrials.gov…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Patient with Lung Cancer Participates in ‘Practice-Changing’ Immunotherapy Research | Dana-Farber Cancer Institute - 3 year(s) ago
Published: June 1, 2022Every school day, when Mike James walks into work at Boston Adult Technical Academy (BATA), he sees an inspiring sign painted by the students: Together, We Can. That philosophy lifted James up after he was diagnosed with early-stage non-small cell lung cancer in August 2019. James leaned on his support network of … Read more
Source: Dana-Farber Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Every school day, when Mike James walks into work at Boston Adult Technical Academy, he sees an inspiring sign painted by the students: Together, We Can. That philosophy lifted James up after he was diagnosed with #nonsmallcelllungcancer in Aug '19. https://t.co/48RhKgLFrU
-
-
Mashup Score: 0Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC - 3 year(s) ago
Background: Evidence suggests that patients with Medicaid experience lower-quality cancer care than those with commercial insurance. Whether this trend persists in the era of personalized medicine is unclear. This study examined the associations between Medicaid (vs commercial) insurance and receipt of biomarker testing, targeted therapy, and overall survival in patients with advanced non–small…
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Study by @cpgYALE et al examines associations between Medicaid insurance and receipt of #biomarker testing and targeted therapy, and explores association with overall survival in patients with advanced #NSCLC: https://t.co/3iXC9c6vvk #LCSM #nonsmallcelllungcancer https://t.co/f0DicHNWKp
-
-
Mashup Score: 0Optimize Local Therapy for Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer to Enhance Survival - 3 year(s) ago
Metastatic non–small cell lung cancer (NSCLC) is highly heterogeneous, and there are patients with limited areas of metastases (oligometastases) or progression (oligoprogression) whose natural history and prognosis can be considerably more favorable. As a result, local therapy may offer these patients a chance at clinically meaningful disease control and/or cure. This review begins by describing…
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Optimize Local Therapy for Oligometastatic and Oligoprogressive #NonSmallCellLungCancer to Enhance Survival: https://t.co/uGC8hxmLDy Review published by @JoeChangMD and @VivekVermaMD of @MDAndersonNews #NSCLC #LCSM https://t.co/7jW8GemshN
-
-
Mashup Score: 0
PURPOSE Durvalumab significantly improves overall survival for patients with unresectable stage III non–small-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT). Building upon that standard of care, COAST is a phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
COAST: phase 2, multidrug platform study of durvalumab alone or in combo w/ oleclumab or monalizumab in unresectable, Stage III #NonSmallCellLungCancer ✅ Both combos improved response & PFS ⏰ for a phase III Read more 👉 https://t.co/aPDf6e4yip #NSCLC #lcsm @DrRoyHerbstYale https://t.co/XmbsnCWLR0
-
-
Mashup Score: 3Publication In Focus: INSIGHT 2 - 3 year(s) ago
In this Publication In Focus feature, hear Professor Egbert Smit discuss the latest INSIGHT 2 study protocol published in Future Oncology.
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #INSIGHT2 trial is investigating the use of combination treatment in MET-amplified #NonSmallCellLungCancer, find out more in @OncologyCentral’s In Focus here >>> https://t.co/MyV5j0yYPr
-
-
Mashup Score: 0Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer - British Journal of Cancer - 3 year(s) ago
The lack of non-invasive methods for detection of early micro-metastasis is a major cause of the poor prognosis of non-small cell lung cancer (NSCLC) brain metastasis (BM) patients. Herein, we aimed to identify circulating biomarkers based on proteomics for the early diagnosis and monitoring of patients with NSCLC BM. Upregulated proteins were detected by secretory proteomics in the…
Source: NatureCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer Read for free: https://t.co/rxdfzDwiFH #Diagnosticmarkers #Nonsmallcelllungcancer #Predictivemarkers https://t.co/j9oia64SDq
-
-
Mashup Score: 0Thomas Brown, MD TDBrownMD Syapse #ASCO 2021 #NonsmallC - 3 year(s) ago
Thomas Brown, MD, Chief Medical Officer, Syapse speaks about ASCO 2021 Abstracts – #9105 – Genomic markers associated with hyperprogression in patients wit
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Podcast - ASCO Abstracts - #9105, #e21047, and #e21121 Thomas Brown, MD @TDBrownMD @Syapse #ASCO 2021 #NonsmallCellLungCancer #NSCLC #Cancer #Research Link to Audio: https://t.co/fR8Or3c1IJ https://t.co/3nKOw9n9Xo
-
-
Mashup Score: 0Thomas Brown, MD TDBrownMD Syapse #ASCO 2021 #NonsmallC - 3 year(s) ago
Thomas Brown, MD, Chief Medical Officer, Syapse speaks about ASCO 2021 Poster – #9105 – Genomic markers associated with hyperprogression in patients with l
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Podcast - Genomic Markers Associated With Hyperprogression In Pts With Lung Cancer Thomas Brown, MD @TDBrownMD @Syapse #ASCO 2021 #NonsmallCellLungCancer #NSCLC #Cancer #Research Link to Audio: https://t.co/NWatcbCUyc https://t.co/rLPmAwCcF7
-
-
Mashup Score: 0Thomas Brown, MD TDBrownMD Syapse #ASCO 2021 #NonsmallC - 3 year(s) ago
Thomas Brown, MD, Chief Medical Officer, Syapse speaks about ASCO 2021 Abstract – #e21047 – Myocarditis as a rare, yet serious adverse event associated wit
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Podcast - Myocarditis As A Rare, Yet Serious Adverse Event Associated With Immune Checkpoint Inhibitors Thomas Brown, MD @TDBrownMD @Syapse #ASCO 2021 #NonsmallCellLungCancer #NSCLC #Cancer #Research Link to Audio: https://t.co/mm4psDOVlj https://t.co/lM16Nst7FE
-
🙌 AENEAS Randomized phase III trial of aumolertinib vs gefinib as 1st line therapy for local advanced/metastatic #NonSmallCellLungCancer w/ EGFR Exon 19 deletion or L858R mutations 👀 Aumolertinib led to improved PFS & similar toxicity https://t.co/NMS52m1S9V #LCSM #nsclc https://t.co/7kx6tutkhf